Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quality of Medicinal Products Biologicals, Regulatory and Compendial Approaches Fouad Atouf, Ph.D. Director, Biologics & Biotechnology.

Similar presentations


Presentation on theme: "Quality of Medicinal Products Biologicals, Regulatory and Compendial Approaches Fouad Atouf, Ph.D. Director, Biologics & Biotechnology."— Presentation transcript:

1 Quality of Medicinal Products Biologicals, Regulatory and Compendial Approaches Fouad Atouf, Ph.D. Director, Biologics & Biotechnology

2 Outline Challenges Associated with Manufacturing and Regulation of Biologics and Biotechnology (B&B) Products U.S. Food and Drug Administration (FDA) and Regulatory Pathways for Biological Products Legal Recognition of USPs Standards USP Activities in Biologics

3 Biological Medicines: Challenges (1) Biological Medicines: Scope of Products –Blood and Blood Products –Cell, Gene, Tissue Therapies –Therapeutic Proteins, Recombinant and Naturally-derived –Vaccines Multi-components (e.g. raw materials) manufacturing: –Potential supply chain issues (e.g. animal derived materials) –Testing of quality of components before manufacturing begins Control of the quality, safety and efficacy of biologicals is difficult, despite technological advances –Orthogonal methods needed to address a single quality aspect –Higher order structure issues are often addressed by using a biological assay

4 Biological Medicines: Challenges (2) Complex manufacturing processes with impact on: –Quality attributes of finished products –Challenging regulatory approval pathways Regulatory approaches: –Biologics = Subset of Drugs –Until recent biosimilars law passed, products approved through either the Federal Food, Drug, and Cosmetic Act (FDCA) or the Public Health Service (PHS Act) pathways Depending on legacy approvals, sponsor preference, FDA Policy, and inter-center agreements

5 Office of the Commissioner Office of Foods –Center for Food Safety and Applied Nutrition –Center for Veterinary Medicine Office of Global Regulatory Operations and Policy –Office of International Programs –Office of Regulatory Affairs Office of Medical Products & Tobacco –Center for Biologics Evaluation and Research (CBER) –Center for Devices and Radiological Health –Center for Drug Evaluation and Research (CDER) –Center for Tobacco Products –Office of Special Medical Programs Office of Operations Regulation of B&B Products within the US FDA

6 Regulation of B&B Products - US FDA CDER (NDAs and BLAs) –Insulin and analogs –Hormones and analogs –Therapeutic protein, natural and recombinant –Monoclonal antibodies –Oligonucleotides –Synthetic peptide CBER (BLAs ) –Blood and Blood components –Plasma products –Medical devices –Vaccines –Allergenic extracts –Cell and gene therapy –Xenotransplantation –Tissue NDA: New Drug Application BLA: Biological License Application

7 Biologics Regulated by CDER IND/NDA (FD&C Act) –Insulin –Growth Hormone –FSH, LH, hCG, TSH –Calcitonin –PTH –Aprotinin –Hyaluronidase –Heparins IND/BLA (PHS Act) –Interferons –T-PA –Erythropoietin –Monoclonal Antibodies –Enzymes IND: Investigational New Drug NDA: New Drug Application BLA: Biological License Application

8 FDCA NDAs: –Substantial Evidence of safety and effectiveness; requires 1+ clinical studies; statutory bases for refusing approval, 505(d) –Abbreviated pathway is ANDA, 505 (j); does not have to submit evidence of the safety and effectiveness of the drug product, because it relies on FDAs previous filing; PHS Act BLAs: –Standard of Safety, Purity and Potency, although considered by FDA to be interchangeable with safety and effectiveness (Biosimilars Scientific Considerations Guidance, p. 3 fn 8) –Even biosimilars require 1 or more clinical studies sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use.... 351(k)(2)(A)(i)(I)(cc); and see FDA Form 356h (Application to Market, 21 CFR 314 & 601) Comparing and Contrasting BLAs and NDAs

9 PHS Act Recognizes Overarching Role of FDCA: –PHS §262 (g): PHS may not be construed as in any way affecting, modifying, repealing, or superseding the provisions of the FDCA. –PHS §262 (j), added by 1997 FDA Modernization Act: The FDCA (including even 505 post-marketing studies, and REMS), applies to biologics approved with a PHS Act BLA, except 505 NDA not required. All FDCA Requirements Except 505 License Apply –IND Approval for Clinical Research FDA Form 1571 –Post-approval adverse event reporting –Labeling not false or misleading –503 Presc Drug Mktng Act re Marketing, Samples, Distribution 505D Pharmaceutical Security –501 & 502 Adulteration and Misbranding requirements GMPs (501(a)(2)(B)) USP Identity/Quality Standards (501(b); 502(e)(3) USP Packaging & Labeling Standards (502(g)) What FDCA Requirements Apply to PHS Act BLAs?

10 §351(k) Biologic Product defined as a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product,..., applicable to the prevention, treatment, or cure of a disease or condition of human beings. PHS §351(i) After March 23, 2020, all legacy FDCA biologics will be deemed to be licensed under PHS §351 (see transition rules BPCI §7002(e)) By 2020, All Biologic Products Licensed With BLA

11 Applicants seeking a BLA will continue to have two options: PHS §351(a), based on a demonstration the biological product is safe, pure and potent. PHS §351(k), which requires one or more clinical studies sufficient to demonstrate safety, purity, and potency in 1 or more appropriate conditions of use, as part of information sufficient for FDA to determine that the biological product is biosimilar to a specified §351(a) reference product, PHS §351(k)(2)((A)(i), and disclosure of confidential information, patent/exclusivity requirements. §351(l) By 2020, All Biologic Products Licensed With BLA (2)

12 Drugs/Biologics (articles) are recognized in USP-NF when a standard is published and an official date is assigned. GN* 2.20 Standards are expressed in terms of an articles Monograph, applicable General Chapters, and General Notices. GN 3.10 Monographs include articles Name, and specifications (with tests and assays) to help ensure Identity, as well as Strength, Quality and Purity. GN 4.10 USP Reference Standards key standard component. GN 5.80 May also include other requirements, e.g. related to Packaging, Storage, and Labeling. GN 4.10 *See USP General Notices www.usp.org www.usp.org Role of USP – What Are Compendial Standards?

13 Adulteration – Drug/biologic shall be deemed adulterated If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standards set forth in such compendium. FDCA 501(b) –Official compendium means the current version of USP or NF deemed official by USP, including any supplements. FDCA 201(j) Current official version is 35 USP-30-NF, 5/1/2012 – 4/30/2013 Tests – Such determination as to strength, quality or purity shall be made in accordance with the tests or methods of assay set forth in such compendium,.... FDCA 501(b) Misbranding – Drug/biologic shall be deemed misbranded if it purports to be a drug the name of which is recognized in [USP-NF], unless packaged and labeled as prescribed therein. FDCA 502(g) Enforcement – USP has no role in enforcement of USP standards; responsibility of FDA and other authorities in U.S. and elsewhere. What is USPs Role in Law?

14 USP B&B Expert Committees and Expert Panels General Chapters Biological Analysis Monographs 1Monographs 2 Viral Testing for Human Plasma Cryopreservation Glycoprotein & Glycan Analysis Residual DNA Testing Immunological Test Methods Viral Clearance Immunogenicity Protein Determination Procedures Viral Vaccines Glycoconjugate Vaccines Chapters Recombinant Therapeutic MAbs GlucagonEpoetin Pharmaceutical Enzyme Preparations Unfractionated Heparin Low Molecular Weight Heparin Insulin Tissue and Tissue- Based Products Plasma Protein Analytical Coagulation Factors Residual Host Cell Proteins (to be formed)

15 USP StandardsBiologicals

16 Horizontal Standards - Procedural Benefits: Access to validated procedures and procedure performance criteria early in development Solid anchor point for product characterization Facilitated comparability during development stages Challenges in Standard Development: Assuring suitability and performance across products and analytical platforms Defining and developing associated reference material(s) Evolution of analytical technology - when is a method ready for the compendium? When is the compendium ready for revision? Determination of equivalence between analytical procedures and establishment of performance criteria

17 Vertical Standards – Monographs Role and Use: Clearly define identity, strength and purity, as well as other important quality attributes at the product level Allow independent testing and verification based on a public standard Considerations for Standard Development: Complexity of specifications and system suitability criteria Biological potency assignments and unit maintenance –Across manufacturers –Internationally Product- specific vs. common product class requirements For well-characterized and legacy products: inclusion and bridging to new analytical technology

18 Official USP Biologics Monographs by Product Class Product Class Number of monographs peptide47 enzyme12 complex extract11 carbohydrate11 glycosaminoglycan9 other5 Tissue product6 IgG/serum9 Blood component/protein 5 Vaccine3

19

20


Download ppt "Quality of Medicinal Products Biologicals, Regulatory and Compendial Approaches Fouad Atouf, Ph.D. Director, Biologics & Biotechnology."

Similar presentations


Ads by Google